Brought to you by 
Series D brings in $40mm for Aileron Therapeutics; second tranche added
22 Jan 2013
Executive Summary
New investors SR One and Excel Medical Fund have co-led Aileron Therapeutics' (developing drug candidates for cancer and inflammation as well as immune, metabolic, and infectious diseases) oversubscribed $40mm Series D venture round. Other first-time backers Lilly Ventures and Roche Venture Fund were joined by returning shareholders Apple Tree Partners and Novartis Venture Fund. SR One and Excel will each contribute one board member. The company will use the proceeds to advance the lead compound from its stapled (synthetically locked) peptides programs into clinical studies next year for either solid tumors or blood cancer. The company has brought in about $61mm since it was formed over four years ago.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D brings in $40mm for Aileron Therapeutics; second tranche added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice